Richard Barteček
Masaryk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Richard Barteček.
Journal of Ect | 2017
Jana Hořínková; Richard Barteček; Sylvie Fedorová
Depression is the most frequent affective disorder after traumatic brain injury (TBI).1 When electroconvulsive therapy (ECT) is considered in patients after TBI, inevitable questions will arise, such as whether the method is indicated, effective, and safe and whether it is necessary to modify the methodology.
European Psychiatry | 2011
Richard Barteček; Jan Juřica; J. Zrůstová; Tomáš Kašpárek; Alexandra Žourková
Introduction Risperidone is an antipsychotic used as the first-line treatment of schizophrenia. Risperidone is metabolised by enzyme CYP2D6. Activity of this enzyme can be predicted by genotypization. Objectives To explore the possibility of different response rate to risperidone in first-episode schizophrenia patients with different CYP2D6 genotype. Aim To asses the utility of CYP2D6 pharmacogenetic testing in patients with schizophrenia treated with risperidone. Methods CYP2D6 genotype was assessed in 22 first-episode schizophrenic patients by use of automatic sequencing of DNA isolated from peripheral leukocytes. PANSS score was assessed every week of treatment until the change in medication or patient release. Response was defined as at least 30% reduction in total PANSS. Differences in response rate between groups were tested by Fishers exact test. Results 10 CYP2D6 extensive metabolisers (EM), 8 intermediate metabolisers (IM) and 4 poor metabolisers (PM) were identified. Criteria for response met 4 EM, 4 IM and 1 PM. Differences in response rate between groups were not statistically significant. Conclusions Although group of IM had higher response rate than EM and PM, differences in response rate did not reach statistical significance. Further differences may be found by extending the sample size. An useful approach would be also to examine differences in occurrence of adverse effects and subjective tolerance of the treatment. Acknowledgement The study was supported by the grant of Czech Ministry of Health No. NS 9676-4/2008.
Archive | 2018
Alena Damborská; Miralena I. Tomescu; Richard Barteček; Dominik Drobisz; Eliška Honzírková; Christoph M. Michel
Archive | 2018
Sylvie Fedorová; Richard Barteček
Archive | 2018
Richard Barteček; Ondřej Bečev; Robert Roman; Petr Sojka; Bojan Kerouš; Fotios Liarokapis; Martin Bareš
Archive | 2018
Jana Hořínková; Richard Barteček
Archive | 2017
Jana Hořínková; Richard Barteček
Archive | 2017
Alena Damborská; Miralena I. Tomescu; Richard Barteček; Eliška Honzírková; Dominik Drobisz; Christoph M. Michel
Archive | 2017
Pavla Linhartová; Jan Širůček; Richard Barteček; Pavel Theiner; Barbora Jeřábková; Daniela Rudišinová; Tomáš Kašpárek
Archive | 2017
Jana Hořínková; Richard Barteček